Botox maker Allergan Inc. ramped up its defense against a $53 billion hostile takeover bid from Valeant Pharmaceuticals International Inc. on Friday by directing Latham & Watkins and Wachtell, Lipton, Rosen & Katz to sue Valeant.

In the 51-page complaint filed in federal district court in Santa Ana, Calif., Allergan claims that Valeant colluded with activist investor Bill Ackman on its unsolicited bid. That enabled Ackman’s hedge fund Pershing Square Capital Management LP to trade on inside information before Valeant announced its takeover offer.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]